Literature DB >> 9729704

Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy.

S J Bachrach1, R S Walter, K Trzcinski.   

Abstract

Fifty-four parents/caretakers of children with cerebral palsy were surveyed regarding their use of antisialorrheic medication for excessive drooling. Glycopyrrolate was used by 37 of 41 respondents, with significant improvement in drooling noted in the vast majority (95%) of cases as indicated by a five-point rating scale. Side effects (dry mouth, thick secretions, urinary retention, or flushing) surfaced in almost half (44%) of the patients but necessitated discontinuation of pharmacologic treatment in less than a third. While larger clinical studies are needed, our preliminary data indicate a trial of glycopyrrolate should be considered in children with cerebral palsy where drooling is a significant problem.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9729704     DOI: 10.1177/000992289803700805

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  13 in total

1.  Effect of botulinum toxin type a on morphology of salivary glands in patients with cerebral palsy.

Authors:  Zee-Ihn Lee; Dong-Hyun Cho; Won-Duck Choi; Dong-Hwi Park; Seung-Deuk Byun
Journal:  Ann Rehabil Med       Date:  2011-10-31

Review 2.  Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions.

Authors:  Karly P Garnock-Jones
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

3.  Treating sialorrhea with transdermal scopolamine. Exploiting a side effect to treat an uncommon symptom in cancer patients.

Authors:  Davide Tassinari; Barbara Poggi; Manuela Fantini; Emiliano Tamburini; Sergio Sartori
Journal:  Support Care Cancer       Date:  2005-04-30       Impact factor: 3.603

Review 4.  Hypersalivation: update of the German S2k guideline (AWMF) in short form.

Authors:  Armin Steffen; Wolfgang Jost; Tobias Bäumer; Dirk Beutner; Sabine Degenkolb-Weyers; Martin Groß; Maria Grosheva; Samer Hakim; Kai G Kahl; Rainer Laskawi; Rebekka Lencer; Jan Löhler; Thekla Meyners; Saskia Rohrbach-Volland; Rainer Schönweiler; Sara-Christina Schröder; Sebastian Schröder; Heidrun Schröter-Morasch; Maria Schuster; Susanne Steinlechner; Roland Urban; Orlando Guntinas-Lichius
Journal:  J Neural Transm (Vienna)       Date:  2019-04-10       Impact factor: 3.575

5.  Social interaction and self-esteem of children with cerebral palsy after treatment for severe drooling.

Authors:  Jan J W van der Burg; Peter H Jongerius; Jacques van Limbeek; Karen van Hulst; Jan J Rotteveel
Journal:  Eur J Pediatr       Date:  2005-09-20       Impact factor: 3.183

6.  [Amyotrophic lateral sclerosis: management of bulbar symptoms].

Authors:  P Kraft; M Beck; A Grimm; C Wessig; K Reiners; K V Toyka
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

7.  Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children.

Authors:  Marian L Evatt
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-20       Impact factor: 2.570

8.  Therapeutic use of botulinum toxin in neurorehabilitation.

Authors:  Domenico Intiso
Journal:  J Toxicol       Date:  2011-09-14

9.  Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions.

Authors:  Robert S Zeller; Jennifer Davidson; Hak-Myung Lee; Paul F Cavanaugh
Journal:  Ther Clin Risk Manag       Date:  2012-01-25       Impact factor: 2.423

10.  Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions.

Authors:  Robert S Zeller; Hak-Myung Lee; Paul F Cavanaugh; Jennifer Davidson
Journal:  Ther Clin Risk Manag       Date:  2012-01-25       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.